drugset / Trial / NCT01727869
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
Timeline
- Start
- 2012-10
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Erlotinib | Small molecule | — | — |
| Subject | REGN1400 | Unknown | — | — |